Arcturus Therapeutics Holdings (ARCT) Return on Capital Employed (2019 - 2026)
Arcturus Therapeutics Holdings (ARCT) posted Return on Capital Employed of 39.46% for Q1 2026, down 24.39% on a QoQ basis from 31.73% in Q4 2025, and down 1102.0% year-over-year from 3.94% in Q1 2025.
Arcturus Therapeutics Holdings (ARCT) Return on Capital Employed (2019 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings' Return on Capital Employed history runs 8 years deep, the most recent figure standing at 39.46% for Q1 2026.
- Quarterly Return on Capital Employed fell 1102.0% year-over-year to 39.46% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 39.46% (down 1102.0% YoY) and the FY2025 annual result came in at 28.12%, up 166.0% from the prior year.
- Return on Capital Employed was 39.46% for Q1 2026 at Arcturus Therapeutics Holdings, down from 31.73% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 20.87% in Q1 2023 and bottomed at 75.19% in Q1 2022.
- A 5-year average of 26.61% and a median of 28.56% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed soared 9606 bps — and 2024, when it sank 6083 bps.
- Arcturus Therapeutics Holdings' Return on Capital Employed stood at 4.97% in 2022, then sank by 535 bps to 21.63% in 2023, then slumped by 52 bps to 32.78% in 2024, then climbed by 3 bps to 31.73% in 2025, then fell by 24 bps to 39.46% in 2026.
- Business Quant data shows ARCT's Return on Capital Employed at 39.46% in Q1 2026, 31.73% in Q4 2025, and 29.67% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Arcturus Therapeutics Holdings | 164.57 Mn | -46.81 Mn | - | -39.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39.46% |
| Dec 31, 2025 | -31.73% |
| Sep 30, 2025 | -29.67% |
| Jun 30, 2025 | -26.49% |
| Mar 31, 2025 | -28.45% |
| Dec 31, 2024 | -32.78% |
| Sep 30, 2024 | -25.97% |
| Jun 30, 2024 | -28.56% |
| Mar 31, 2024 | -39.97% |
| Dec 31, 2023 | -21.63% |
| Sep 30, 2023 | 17.26% |
| Jun 30, 2023 | 12.22% |
| Mar 31, 2023 | 20.87% |
| Dec 31, 2022 | 4.97% |
| Sep 30, 2022 | -61.35% |
| Jun 30, 2022 | -66.44% |
| Mar 31, 2022 | -75.19% |
| Dec 31, 2021 | -64.57% |
| Sep 30, 2021 | -60.69% |
| Jun 30, 2021 | -41.43% |